Perspectives of general practitioners about a collaborative asthma care model in primary care

Qazi, Anila; Armour, Carol; Saini, Bandana

doi:10.1080/02770903.2020.1823408

Cited by 7 publications

(19 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The included articles aimed to: (i) characterise the clinical and non-clinical activities that a pharmacist can perform in general practice [ 32 , 39 , 42 , 44 , 46 , 51 – 53 , 55 , 56 , 62 ], (ii) explore the pharmacist recommendations and general practitioner acceptance rates regarding medication-related decision-making in general practice [ 43 , 49 – 51 ], and (iii) explain the stakeholders’ perspectives, barriers and facilitators of the inclusion of a pharmacist into general practice [ 40 , 41 , 45 , 47 , 48 , 51 , 54 , 57 – 59 , 61 ]. The included articles utilised designs that were qualitative (40%, n = 10) [ 40 , 42 , 45 , 47 , 48 , 55 , 58 , 59 , 61 , 62 ], quantitative non-randomised control (32%, n = 8) [ 39 , 43 , 46 , 49 , 50 , 52 , 56 , 60 ], quantitative descriptive (8%, n = 2) [ 32 , 41 ], and mixed-method (20%, n = 5) [ 44 , 51 , 53 , 54 , 57 ].…”

Section: Resultsmentioning

confidence: 99%

“…The articles which utilised a quantitative non-RCT design (32%, n = 8) or a mixed-method design (20%, n = 5) fulfilled 2–4 criteria [ 39 , 43 , 44 , 46 , 49 – 54 , 56 , 57 , 60 ], and quantitative descriptive design (8%, n = 2) fulfilled 3–4 criteria in the MMAT [ 31 , 40 ]. Overall, five articles (20%) fulfilled all criteria [ 44 , 46 , 47 , 59 , 61 ], eight articles (32%) fulfilled 4 criteria [ 32 , 40 , 42 , 46 , 49 , 50 , 54 , 62 ], ten articles (40%) fulfilled 3 criteria [ 39 , 41 , 52 , 52 , 54 – 58 , 60 ], and two articles (8%) fulfilled 2 criteria [ 42 , 43 ] for their particular research design using the MMAT. Details of the quality appraisal of the included articles are provided in S3 Table .…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

General practice pharmacists in Australia: A systematic review

et al. 2021

View full text Add to dashboard Cite

Background The inclusion of pharmacists into general practices in Australia has expanded in recent years. This systematic review aimed to synthesise the literature of qualitative and quantitative studies, and identify the knowledge gaps, related to pharmacists working in general practice in Australia. Methods This systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. PubMed, EBSCOhost, EMBASE, and the Cochrane Library were searched from the inception of databases to January 2021. The search was focused on studies investigating general practice pharmacists in Australia. The quality of each study was appraised using the Mixed Method Appraisal Tool criteria. The narrative synthesis approach was utilised to describe data due to the heterogeneity among study designs and measures. Results Twenty-five studies were included in this review. General practice pharmacists engaged in various non-dispensing patient care services, with medication management reviews being the primary activity reported. General practice pharmacists’ characteristics and an environment with a willingness of collaboration were the notable influencing factors for successfully including pharmacists in general practices. Factors that posed a challenge to the adoption of general practice pharmacists were lack of funding and other resources, poorly defined roles, and absence of mentoring/training. Conclusion This review has summarised the characteristics, activities, benefits, barriers, and facilitators of including pharmacists in general practices in Australia. General practice pharmacists are well accepted by stakeholders, and they can engage in a range of patient-centred activities to benefit patients. There is a need for more robust research to explore the patient and economic outcomes related to clinical activities that a pharmacist can perform in general practice, as a foundation to developing an appropriate and sustainable funding model. The findings of this review will be beneficial for pharmacists, researchers, policymakers, and readers who wish to implement the role of general practice pharmacists in the future.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

General practice pharmacists in Australia: A systematic review

et al. 2021

View full text Add to dashboard Cite

show abstract

“…As this condition affects asthma control, its treatment is expected to improve asthma outcome (Evidence A). [ 118 119 120 ] Treatment includes nasal saline washes, nasal steroids, leukotriene receptor antagonists (LTRAs), and antihistamines. Concomitant rhinosinusitis is recommended to be treated appropriately as well.…”

Section: Section 6: Pharmacological Management In Adults and Adolescementioning

confidence: 99%

“… ACT score ≥20 (controlled status) An anti-inflammatory reliever therapy in the form of ICS/formoterol combination on as-needed basis (Evidence A)[ 114 121 ] An alternative option is to use SABA together with low-dose ICS both on as-needed basis (Evidence B)[ 110 111 122 ] Maintenance daily low-dose ICS is recommended in special situations: For patients with symptoms more than twice a week and risk factors for acute attack (severe attacks in the past 12 months or prior history of admission to an ICU, especially if intubated) or evidence of fixed airway obstruction (Evidence B). [ 117 120 123 ] Early introduction of ICS leads to greater improvement of FEV 1 and lower the future doses of ICS. [ 123 ] ACT score 16–19 (partially controlled status) Low-dose ICS for patients with an ACT score of 16–19 (Evidence A).…”

Section: Section 6: Pharmacological Management In Adults and Adolescementioning

confidence: 99%

“…For patients with symptoms more than twice a week and risk factors for acute attack (severe attacks in the past 12 months or prior history of admission to an ICU, especially if intubated) or evidence of fixed airway obstruction (Evidence B). [ 117 120 123 ] Early introduction of ICS leads to greater improvement of FEV 1 and lower the future doses of ICS. [ 123 ]…”

Section: Section 6: Pharmacological Management In Adults and Adolescementioning

confidence: 99%

See 1 more Smart Citation

The Saudi Initiative for Asthma - 2021 Update: Guidelines for the diagnosis and management of asthma in adults and children

et al. 2021

View full text Add to dashboard Cite

The Saudi Initiative for Asthma 2021 (SINA-2021) is the fifth version of asthma guidelines for the diagnosis and management of asthma for adults and children, which is developed by the SINA group, a subsidiary of the Saudi Thoracic Society. The main objective of the SINA is to have guidelines that are up to date, simple to understand, and easy to use by healthcare workers dealing with asthma patients. To facilitate achieving the goals of asthma management, the SINA panel approach is mainly based on the assessment of symptom control and risk for both adults and children. The approach to asthma management is aligned for age groups: adults, adolescents, children aged 5–12 years, and children aged less than 5 years. SINA guidelines have focused more on personalized approaches reflecting better understanding of disease heterogeneity with the integration of recommendations related to biologic agents, evidence-based updates on treatment, and the role of immunotherapy in management. Medication appendix has also been updated with the addition of recent evidence, new indications for existing medication, and new medications. The guidelines are constructed based on the available evidence, local literature, and the current situation at national and regional levels. There is also an emphasis on patient–doctor partnership in the management that also includes a self-management plan.

show abstract